Alexandre Vert is the founder of Osivax. Osivax has raised $42M in total funding. Latest round: Series B. Based in Lyon, France.
Alexandre Le Vert is the CEO and Co-founder of Osivax, a biopharmaceutical company developing broad-spectrum vaccines against highly mutating infectious viruses. Osivax utilizes its oligoDOM™ nanoparticle platform technology to create pan-respiratory virus vaccines. The company has secured funding, including a €8 million Series A round in 2019 and a €10 million first close of its Series B financing in 2025, to advance its vaccine candidates.
Full founder directory · Investor directory · Company funding database · Fundraising library